EI
CBIO

Ellevest Inc’s Crescent Biopharma CBIO Stock Holding History

Ellevest Inc’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2
Closed – – 1206
2020
Q1 		$0 Buy
+2
New +$764 ﹤0.01% 1167

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ellevest Inc's CBIO Position: Q2 2020 in Review

Ellevest Inc sold out of Crescent Biopharma (CBIO) in Q2 2020, closing a stake of 2 shares.

Ellevest Inc first reported a position in CBIO in Q1 2020 and held it in 1 quarter. The position peaked at $0 in Q1 2020. 87 funds tracked by Wall St. Rank hold CBIO as of Q2 2020.

  • Ellevest Inc reported no remaining Crescent Biopharma position as of Q2 2020 after selling out during the quarter.
  • Ellevest Inc sold 2 Crescent Biopharma shares in Q2 2020.
  • Ellevest Inc first reported a position in Crescent Biopharma in Q1 2020 and held it in 1 quarter.
  • Ellevest Inc's Crescent Biopharma position peaked at $0 in Q1 2020.
  • 87 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2020.

Based on Ellevest Inc's 13F filing for Q2 2020, filed 6 Jul 2020.